• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation.

作者信息

Gu L, Strickley R G, Chi L H, Chowhan Z T

机构信息

Institute of Pharmaceutical Sciences, Syntex Research, Palo Alto, California 94304.

出版信息

Pharm Res. 1990 Apr;7(4):379-83. doi: 10.1023/a:1015871406549.

DOI:10.1023/a:1015871406549
PMID:2362911
Abstract

The drug-excipient incompatibility screen for moexipril hydrochloride (1) using various isothermal stress methods is reported herein. It was found that most of the commonly used filters, disintegrants, lubricants, glidants, and coating agents were incompatible with 1 in dry powder mixtures; moisture and basic (or alkalizing) agents were determined to be the dominant destabilizing factors. In wet granulations, basic agents, however, were found to suppress drug degradation even in the presence of moisture. Supported by the product distribution studies, the stabilization is proposed to involve the neutralization of the acidic drug by the basic excipients.

摘要

相似文献

1
Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation.
Pharm Res. 1990 Apr;7(4):379-83. doi: 10.1023/a:1015871406549.
2
Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.药用辅料对其固体制剂中血管紧张素转化酶抑制剂稳定性的影响。
Drug Dev Ind Pharm. 2013 Jan;39(1):51-61. doi: 10.3109/03639045.2012.657644. Epub 2012 Feb 20.
3
Effect of carrier excipient and processing on stability of indorenate hydrochloride/excipient mixtures.载体辅料及加工过程对盐酸茚托雷酯/辅料混合物稳定性的影响
Pharm Dev Technol. 2001 Nov;6(4):551-61. doi: 10.1081/pdt-120000293.
4
Compatibility of sennoside A and B with pharmaceutical excipients.番泻苷A和B与药用辅料的相容性。
Pharmazie. 2004 Sep;59(9):728-30.
5
The influence of pharmaceutical excipients on quinapril hydrochloride stability.
Acta Pol Pharm. 2005 May-Jun;62(3):189-93.
6
First order derivative spectrophotometric and HPLC methods for determination of moexipril hydrochloride in the pure form, pharmeceutical formulations and evaluation of its stability.一阶导数分光光度法和高效液相色谱法用于测定纯品、药物制剂中的盐酸莫昔普利及其稳定性评估。
Acta Pol Pharm. 2012 May-Jun;69(3):389-95.
7
Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.新型血管紧张素转换酶抑制剂盐酸莫昔普利的药理与毒理学研究
Arzneimittelforschung. 1997 Feb;47(2):132-44.
8
Influence of humidity and hydroxypropyl cellulose, hydroxypropylmethyl cellulose, glyceryl behenate or magnesium stearate on the degradation kinetics of quinapril hydrochloride in solid phase.湿度以及羟丙基纤维素、羟丙基甲基纤维素、山嵛酸甘油酯或硬脂酸镁对盐酸喹那普利在固相中降解动力学的影响。
Acta Pol Pharm. 2010 Jan-Feb;67(1):99-102.
9
A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.精细辅料在载药干粉吸入剂混合物中的新作用:混合过程中药物颗粒解团聚作用的揭示。
AAPS PharmSciTech. 2017 Nov;18(8):2862-2870. doi: 10.1208/s12249-017-0767-4. Epub 2017 Apr 18.
10
Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing.通过药物-辅料相容性测试选择格列吡嗪缓释制剂的辅料
J Pharm Biomed Anal. 2005 Jul 15;38(4):633-44. doi: 10.1016/j.jpba.2005.02.026. Epub 2005 Mar 23.

引用本文的文献

1
A Rapid 3-Day Excipient Screening Methodology and its Application in Identifying Chemical Stabilizers for Solid Formulations with Mixed Mechanisms of Degradation.一种快速 3 天辅料筛选方法及其在鉴定具有混合降解机制的固体制剂化学稳定剂中的应用。
AAPS PharmSciTech. 2024 Jan 5;25(1):12. doi: 10.1208/s12249-023-02730-5.
2
Compatibility study of rosmarinic acid with excipients used in pharmaceutical solid dosage forms using thermal and non-thermal techniques.使用热分析和非热分析技术对迷迭香酸与药物固体剂型中所用辅料的相容性研究。
Saudi Pharm J. 2019 Dec;27(8):1138-1145. doi: 10.1016/j.jsps.2019.09.010. Epub 2019 Sep 25.
3

本文引用的文献

1
Stability of solids and solid dosage forms.固体及固体剂型的稳定性
J Pharm Sci. 1974 Jan;63(1):1-14. doi: 10.1002/jps.2600630103.
2
Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085.新型二肽血管紧张素转换酶抑制剂RS-10085的二酮哌嗪形成、水解及差向异构化
Pharm Res. 1987 Oct;4(5):392-7. doi: 10.1023/a:1016430211480.
3
Preformulation stability studies of the new dipeptide angiotensin-converting enzyme inhibitor RS-10029.
Physicomechanical characterization and optimization of EDTA-mPEG and Avicel®-EDTA-mPEG in situ melt dispersion mini-pellets.
EDTA-mPEG 和 Avicel®-EDTA-mPEG 原位熔融分散微型丸的物理机械特性表征和优化。
AAPS PharmSciTech. 2013 Sep;14(3):935-49. doi: 10.1208/s12249-013-9979-4. Epub 2013 Jun 4.
4
Impact of excipient interactions on solid dosage form stability.辅料相互作用对固体制剂稳定性的影响。
Pharm Res. 2012 Oct;29(10):2660-83. doi: 10.1007/s11095-012-0782-9. Epub 2012 Jun 16.
5
Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.辅料中的反应性杂质:药物-辅料不相容性的剖析、鉴定和缓解。
AAPS PharmSciTech. 2011 Dec;12(4):1248-63. doi: 10.1208/s12249-011-9677-z. Epub 2011 Sep 27.
6
Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.制剂和加工因素对左甲状腺素钠五水合物稳定性的影响。
AAPS PharmSciTech. 2010 Jun;11(2):818-25. doi: 10.1208/s12249-010-9434-8. Epub 2010 May 8.
7
Ionization states in the microenvironment of solid dosage forms: effect of formulation variables and processing.固体剂型微环境中的离子化状态:制剂变量和工艺的影响
Pharm Res. 2006 Oct;23(10):2454-68. doi: 10.1007/s11095-006-9085-3. Epub 2006 Aug 24.
8
Effect of carbonate salts on the kinetics of acid-catalyzed dimerization of adefovir dipivoxil.碳酸盐对阿德福韦酯酸催化二聚反应动力学的影响。
Pharm Res. 2000 Sep;17(9):1098-103. doi: 10.1023/a:1026457729708.
Pharm Res. 1988 Dec;5(12):765-71. doi: 10.1023/a:1015984617472.
4
Recent developments in the design of angiotensin-converting enzyme inhibitors.
Med Res Rev. 1985 Oct-Dec;5(4):483-531. doi: 10.1002/med.2610050405.